Doral Healthcare Finance (DHF) announced it has provided a three-year $7 million revolving line of credit to Zynex, Inc. and subsidiaries.

Proceeds from the transaction will be used to pay off existing debt and for growth. Zynex develops, manufactures and markets non-invasive FDA-CE marked medical devices for pain relief, stroke and spinal cord rehabilitation, neurological and cardiac monitoring.

�DHF successfully structured a working capital line that addressed the two restrictions that were in place with Zynex�s current lender; a line large enough to support Zynex�s operating cash flow needs and the flexibility in the line to accommodate potential acquisitions,� said Jennifer Sheasgreen, DHF managing director.

Thomas Sandgaard, president and CEO of Zynex, commented, �This new line of credit provides us substantial flexibility to execute our strategic business plan. We are excited to work with DHF, as they understand our business model and believe they will be a great partner for our future.�

Doral Healthcare Finance is engaged in providing asset-based lending, working capital lines of credit to providers of goods and services in the healthcare industry nationwide, including hospitals, home healthcare agencies and long-term care facilities with financing needs from one million to $20 million.